Gerd R Burmester

960 total papers · 62.8k total citations
595 papers, 28.1k citations indexed

About

Gerd R Burmester is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Gerd R Burmester has authored 595 papers receiving a total of 28.1k indexed citations (citations by other indexed papers that have themselves been cited), including 414 papers in Rheumatology, 177 papers in Immunology and 152 papers in Hematology. Recurrent topics in Gerd R Burmester's work include Rheumatoid Arthritis Research and Therapies (320 papers), Systemic Lupus Erythematosus Research (139 papers) and Autoimmune and Inflammatory Disorders Research (136 papers). Gerd R Burmester is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (320 papers), Systemic Lupus Erythematosus Research (139 papers) and Autoimmune and Inflammatory Disorders Research (136 papers). Gerd R Burmester collaborates with scholars based in Germany, United States and United Kingdom. Gerd R Burmester's co-authors include Thomas Dörner, Janet Pope, Eugen Feist, Thomas Häupl, Iain B. McInnes, Michael Sittinger, Robert Winchester, Ronald van Vollenhoven, Vibeke Strand and Paul Emery and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Gerd R Burmester

574 papers receiving 27.2k citations

Hit Papers

Rheumatoid arthritis 2005 2026 2012 2019 2018 2017 2013 2020 2005 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Rheumatoid arthritis
    2018 1.6k citations Josef S Smolen, Daniel Aletaha et al. Nature Reviews Disease Primers profile →
  2. Novel treatment strategies in rheumatoid arthritis
    2017 788 citations Gerd R Burmester, Janet Pope The Lancet profile →
  3. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
    2013 548 citations Gerd R Burmester, Ricardo Blanco et al. The Lancet profile →
  4. The etiology of rheumatoid arthritis
    2020 532 citations Hans Ulrich Scherer, Thomas Häupl et al. profile →
  5. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 501 citations Christian Antoni, Arthur Kavanaugh et al. Arthritis & Rheumatism profile →
  6. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
    2012 429 citations Gerd R Burmester, Remo Panaccione et al. Annals of the Rheumatic Diseases profile →
  7. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    2018 291 citations Gerd R Burmester, Joel M. Kremer et al. The Lancet profile →
  8. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
    2020 192 citations Alexandre Sepriano, Andreas Kerschbaumer et al. Annals of the Rheumatic Diseases profile →
  9. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
    2020 178 citations Stanley Cohen, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases profile →
  10. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
    2023 118 citations Gerd R Burmester, Stanley Cohen et al. RMD Open profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gerd R Burmester 15.5k 8.8k 5.3k 3.4k 3.1k 595 28.1k
Ben A. C. Dijkmans 18.3k 1.2× 6.3k 0.7× 6.2k 1.2× 2.8k 0.8× 2.4k 0.8× 332 24.9k
Josef S Smolen 25.4k 1.6× 10.1k 1.1× 9.6k 1.8× 3.2k 1.0× 3.6k 1.1× 508 35.2k
Yoshiya Tanaka 14.4k 0.9× 9.6k 1.1× 5.2k 1.0× 5.7k 1.7× 3.0k 0.9× 1.1k 30.1k
Mark C. Genovese 14.1k 0.9× 8.5k 1.0× 6.5k 1.2× 2.1k 0.6× 2.9k 0.9× 317 22.7k
Edward Keystone 17.0k 1.1× 6.8k 0.8× 7.9k 1.5× 1.8k 0.5× 2.8k 0.9× 404 24.4k
Ravinder N. Maini 17.2k 1.1× 10.2k 1.2× 6.1k 1.1× 5.1k 1.5× 5.1k 1.6× 271 31.4k
Paul P. Tak 13.9k 0.9× 11.8k 1.3× 4.4k 0.8× 8.5k 2.5× 3.4k 1.1× 458 33.3k
Michael H. Weisman 14.9k 1.0× 6.1k 0.7× 5.0k 0.9× 2.2k 0.7× 2.4k 0.8× 340 22.2k
Ronald van Vollenhoven 20.5k 1.3× 9.9k 1.1× 6.8k 1.3× 1.8k 0.5× 4.8k 1.5× 508 27.5k
Ferdinand C. Breedveld 15.2k 1.0× 5.4k 0.6× 5.4k 1.0× 2.2k 0.7× 3.4k 1.1× 182 21.9k

Countries citing papers authored by Gerd R Burmester

Since Specialization
Citations

This map shows the geographic impact of Gerd R Burmester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd R Burmester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd R Burmester more than expected).

Fields of papers citing papers by Gerd R Burmester

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerd R Burmester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd R Burmester. The network helps show where Gerd R Burmester may publish in the future.

Co-authorship network of co-authors of Gerd R Burmester

This figure shows the co-authorship network connecting the top 25 collaborators of Gerd R Burmester. A scholar is included among the top collaborators of Gerd R Burmester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerd R Burmester. Gerd R Burmester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John R. Speakman Breakdown of academic impact, for papers by Nicholas C. Coops Breakdown of academic impact, for papers by R. Wiesendanger Breakdown of academic impact, for papers by Suresh S. Ramalingam Breakdown of academic impact, for papers by Oliver Distler Breakdown of academic impact, for papers by Petros Koutrakis Breakdown of academic impact, for papers by Iván K. Schuller Breakdown of academic impact, for papers by Weimin Liu
Rankless by CCL
2026